{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:22:21Z","timestamp":1775791341759,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Objectives:<\/jats:title><jats:p>Circularly permuted tumor necrosis factor-related apoptosis-inducing ligand (CPT), or CPT, is a novel antitumor drug candidate. This phase 1b study evaluated the safety, tolerability, pharmacokinetics (PK), and efficacy of single-agent CPT in patients with relapsed or refractory multiple myeloma (RRMM), and aimed to identify the recommended dose for the phase 2 study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods:<\/jats:title><jats:p>Patients received single or multiple doses (once daily for 5 consecutive days per 21-d cycle) of CPT intravenous infusion at doses of 5, 6.5, 8, 10, and 15\u2009mg\/kg, to determine the maximum tolerated dose, dose-limiting toxicities, safety, and tolerability. PK were evaluated. Preliminary efficacy was assessed after each treatment cycle.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Twenty-nine RRMM patients received CPT. Neither the dose-limiting toxicity nor the maximum tolerated dose were identified. The most common treatment-related adverse events were liver enzyme elevations (eg, elevation of aspartate aminotransferase and alanine aminotransferase), hematological abnormalities (eg, leukopenia and neutropenia), fever, fatigue, and vomiting. CPT had a terminal half-life of 0.90 to 1.27 hours at the 5 dose levels, and no accumulation was observed with repeated doses. Safety and PK profiles were similar across the 5 dose cohorts. The overall response rate (complete and partial response) was 18.5%. The clinical benefit rate (complete, partial, and minimal response) was 33.3%. Sixteen patients did not respond to CPT (no change and progressive disease). Patients treated with higher doses of CPT appeared to have better responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>CPT was safe and well tolerated by RRMM patients, and doses between 8 and 15\u2009mg\/kg were recommended for the phase 2 study.<\/jats:p><\/jats:sec>","DOI":"10.1097\/coc.0000000000000404","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T19:20:45Z","timestamp":1505848845000},"page":"1008-1014","source":"Crossref","is-referenced-by-count":12,"title":["A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1097","volume":"41","author":[{"given":"Jian","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Hematology, Chang Zheng Hospital, Second Military Medical University, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozhong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Departmentof Hematology, Peking University Third Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Friendship Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jinan Military General Hospital, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifang","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Sunbio Biotech Co. Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chang Zheng Hospital, Second Military Medical University, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Beijing Sunbio Biotech Co. Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[{"name":"Beijing Sunbio Biotech Co. Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing Sunbio Biotech Co. Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.leu.2401501","article-title":"TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells","volume":"13","author":"Gazitt","year":"1999","journal-title":"Leukemia"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1038\/sj.onc.1206945","article-title":"Alterations in the apoptotic machinery and their potential role in anticancer drug resistance","volume":"22","author":"Kaufmann","year":"2003","journal-title":"Oncogene"},{"key":"R6-20230903","first-page":"1391","article-title":"Apoptosis, p53, and tumor cell sensitivity to anticancer agents","volume":"59","author":"Brown","year":"1999","journal-title":"Cancer Res"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in cell death and human cancers","volume":"3","author":"Ozaki","year":"2011","journal-title":"Cancers (Basel)"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1745-7254.2005.00206.x","article-title":"Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand","volume":"26","author":"Fang","year":"2005","journal-title":"Acta Pharmacol Sin"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2001.25173a","article-title":"Is TRAIL hepatotoxic?","volume":"34","author":"Gores","year":"2001","journal-title":"Hepatology"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J Clin Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"e109756","DOI":"10.1371\/journal.pone.0109756","article-title":"Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4","volume":"9","author":"Bychkov","year":"2014","journal-title":"PLoS One"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/NEN.0000000000000129","article-title":"Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex","volume":"73","author":"Koschny","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2407-13-140","article-title":"TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages","volume":"13","author":"Yuan","year":"2013","journal-title":"BMC Cancer"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.critrevonc.2012.08.001","article-title":"Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?","volume":"85","author":"de Wilt","year":"2013","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201810000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T20:28:01Z","timestamp":1750883281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201810000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000404","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}